Anticancer Compound Plumbagin and Its Molecular Targets: A Structural Insight into the Inhibitory Mechanisms Using Computational Approaches

Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is a naphthoquinone derivative from the roots of plant Plumbago zeylanica and belongs to one of the largest and diverse groups of plant metabolites. The anticancer and antiproliferative activities of plumbagin have been observed in animal models as well as in cell cultures. Plumbagin exerts inhibitory effects on multiple cancer-signaling proteins, however, the binding mode and the molecular interactions have not yet been elucidated for most of these protein targets. The present study is the first attempt to provide structural insights into the binding mode of plumbagin to five cancer signaling proteins viz. PI3Kγ, AKT1/PKBα, Bcl-2, NF-κB, and Stat3 using molecular docking and (un)binding simulation analysis. We validated plumbagin docking to these targets with previously known important residues. The study also identified and characterized various novel interacting residues of these targets which mediate the binding of plumbagin. Moreover, the exact modes of inhibition when multiple mode of inhibition existed was also shown. Results indicated that the engaging of these important interacting residues in plumbagin binding leads to inhibition of these cancer-signaling proteins which are key players in the pathogenesis of cancer and thereby ceases the progression of the disease.

[1]  D. Knighton,et al.  Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. , 2010, ACS medicinal chemistry letters.

[2]  G. Russo Ins and outs of dietary phytochemicals in cancer chemoprevention. , 2007, Biochemical pharmacology.

[3]  P. Srinivas,et al.  Structure activity relationship of plumbagin in BRCA1 related cancer cells , 2013, Molecular carcinogenesis.

[4]  Kaushik Raha,et al.  Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. , 2010, ACS medicinal chemistry letters.

[5]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[6]  Aamir Ahmad,et al.  Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. , 2012, Bioorganic & medicinal chemistry letters.

[7]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[8]  P. Kuo,et al.  Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[9]  P. Yue,et al.  Targeting STAT3 in cancer: how successful are we? , 2009, Expert opinion on investigational drugs.

[10]  N. Udupa,et al.  Niosomal Plumbagin with Reduced Toxicity and Improved Anticancer Activity in BALB/C Mice , 1996, The Journal of pharmacy and pharmacology.

[11]  Aris Persidis,et al.  Cancer multidrug resistance , 1999, Nature Biotechnology.

[12]  John Calvin Reed Promise and problems of Bcl-2 antisense therapy. , 1997, Journal of the National Cancer Institute.

[13]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[14]  N. Jing,et al.  Targeting Stat3 in cancer therapy. , 2005, Anti-cancer drugs.

[15]  P. Workman,et al.  Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors , 2011, Current medicinal chemistry.

[16]  Michael Karin,et al.  The IKK NF-kappa B system: a treasure trove for drug development. , 2004, Nature reviews. Drug discovery.

[17]  John Calvin Reed,et al.  Synthesis and biological evaluation of Apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2010, Journal of medicinal chemistry.

[18]  James B. Mitchell,et al.  Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. , 2004, Cancer research.

[19]  J. Baell,et al.  Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. , 2002, Biochemical pharmacology.

[20]  Zhiwei Wang,et al.  Plumbagin‐induced apoptosis of human breast cancer cells is mediated by inactivation of NF‐κB and Bcl‐2 , 2008, Journal of cellular biochemistry.

[21]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[22]  S. Morimoto,et al.  Construction and expression of specificity-improved single-chain variable fragments against the bioactive naphthoquinone, plumbagin. , 2009, Biological & pharmaceutical bulletin.

[23]  C. Sardet,et al.  Post-activation Turn-off of NF-κB-dependent Transcription Is Regulated by Acetylation of p65* , 2003, The Journal of Biological Chemistry.

[24]  S. Dasgupta,et al.  A spectroscopic investigation into the interactions of 3′‐O‐carboxy esters of thymidine with bovine serum albumin , 2009, Biopolymers.

[25]  L. O’Neill,et al.  Studies into the Effect of the Tyrosine Kinase Inhibitor Herbimycin A on NF-κB Activation in T Lymphocytes EVIDENCE FOR COVALENT MODIFICATION OF THE p50 SUBUNIT (*) , 1995, The Journal of Biological Chemistry.

[26]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Aggarwal,et al.  Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-κB Activation and NF-κB-regulated Gene Products Through Modulation of p65 and IκBα Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents* , 2006, Journal of Biological Chemistry.

[28]  K. Ye PIKE/nuclear PI 3‐kinase signaling in preventing programmed cell death , 2005, Journal of cellular biochemistry.

[29]  Aamir Ahmad,et al.  Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. , 2009, Mutagenesis.

[30]  B. Stanley,et al.  Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007 .

[31]  B. Aggarwal,et al.  Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Sardet,et al.  Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. , 2003, The Journal of biological chemistry.

[33]  C. Lindsley,et al.  Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. , 2007, Current topics in medicinal chemistry.

[34]  S. Becker,et al.  Three-dimensional structure of the Stat3β homodimer bound to DNA , 1998, Nature.

[35]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[36]  Li Yang,et al.  Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. , 2009, Journal of medicinal chemistry.

[37]  S. Joos,et al.  The role of Bcl-2 family members in tumorigenesis. , 2004, Biochimica et biophysica acta.

[38]  Massimo Libra,et al.  Akt as a therapeutic target in cancer. , 2008, Expert opinion on therapeutic targets.

[39]  Didier Devaurs,et al.  MoMA-LigPath: a web server to simulate protein–ligand unbinding , 2013, Nucleic Acids Res..

[40]  Bipul R. Acharya,et al.  The natural naphthoquinone plumbagin exhibits antiproliferative activity and disrupts the microtubule network through tubulin binding. , 2008, Biochemistry.

[41]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[42]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[43]  M. Krishnaswamy,et al.  Plumbagin: A study of its anticancer, antibacterial & antifungal properties. , 1980, Indian journal of experimental biology.

[44]  Jing Ma,et al.  A Novel Sequence in the Coiled-coil Domain of Stat3 Essential for Its Nuclear Translocation* , 2003, Journal of Biological Chemistry.

[45]  T. Tsai,et al.  Plumbagin, Isolated from Plumbago zeylanica, Induces Cell Death through Apoptosis in Human Pancreatic Cancer Cells , 2010, Pancreatology.

[46]  B. Aggarwal,et al.  5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization , 2010, Molecular Cancer Research.

[47]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[48]  James B. Mitchell,et al.  Nuclear Factor-κB is an Important Modulator of the Altered Gene Expression Profile and Malignant Phenotype in Squamous Cell Carcinoma , 2004, Cancer Research.

[49]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[50]  Huan Yang,et al.  The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.

[51]  Kam Y. J. Zhang,et al.  Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3 , 2001, Nature Cell Biology.

[52]  Y. Ben-Neriah,et al.  NF-kappaB inhibition: a double-edged sword in cancer? , 2006, European journal of cancer.

[53]  H. J. Kim,et al.  NF-κB and IKK as therapeutic targets in cancer , 2006, Cell Death and Differentiation.

[54]  G. Srinivas,et al.  Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  R. Sarkar,et al.  Synthesis of plumbagin derivatives and their inhibitory activities against Ehrlich ascites carcinoma in vivo and Leishmania donovani Promastigotes in vitro , 2002, Phytotherapy research : PTR.

[56]  I. Enyedy,et al.  Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. , 2001, Journal of medicinal chemistry.

[57]  J. Turkson,et al.  STAT proteins: novel molecular targets for cancer drug discovery , 2000, Oncogene.

[58]  B. Aggarwal,et al.  Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappaB activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents. , 2006, The Journal of biological chemistry.

[59]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[60]  A. Martelli,et al.  Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? , 2006, Cellular signalling.

[61]  H. J. Kim,et al.  NF-kappaB and IKK as therapeutic targets in cancer. , 2006, Cell death and differentiation.

[62]  G. Dewson,et al.  Bcl-2 family-regulated apoptosis in health and disease , 2010 .

[63]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[64]  Thierry Siméon,et al.  A path planning approach for computing large-amplitude motions of flexible molecules , 2005, ISMB.

[65]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[66]  K. Kinzler,et al.  A frequent kinase domain mutation that changes the interaction between PI3Kα and the membrane , 2009, Proceedings of the National Academy of Sciences.

[67]  B. Hellman,et al.  Genotoxicity of plumbagin and its effects on catechol and NQNO-induced DNA damage in mouse lymphoma cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[68]  M. A. Akbarsha,et al.  Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. , 2008, Anticancer research.

[69]  P. Sachdanandam,et al.  Effect of plumbagin on some glucose metabolising enzymes studied in rats in experimental hepatoma , 1993, Molecular and Cellular Biochemistry.

[70]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[71]  M. Toi,et al.  Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.

[72]  Z. Nikolovska-Coleska,et al.  Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review , 2012, Expert opinion on therapeutic patents.

[73]  L. Johnson,et al.  Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.

[74]  S. Korsmeyer,et al.  Antiapoptotic BCL-2 is required for maintenance of a model leukemia. , 2004, Cancer cell.

[75]  S. Agrawal,et al.  Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, Plumbagin* , 2009, The Journal of Biological Chemistry.

[76]  M. Aziz,et al.  Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. , 2008, Cancer research.

[77]  Y. Shih,et al.  Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase‐2 and urokinase‐ plasminogen activator , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[78]  A. Gillum,et al.  Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. , 2002, Antisense & nucleic acid drug development.

[79]  N. Varin‐Blank,et al.  A STAT3-inhibitory hairpin decoy oligodeoxynucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line , 2012, Molecular Cancer.

[80]  Y. Ben-Neriah,et al.  NF-κB inhibition: A double-edged sword in cancer? , 2006 .

[81]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[82]  N. Udupa,et al.  Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. , 1997, Indian journal of physiology and pharmacology.

[83]  Shivendra V. Singh,et al.  Plumbagin-induced Apoptosis in Human Prostate Cancer Cells is Associated with Modulation of Cellular Redox Status and Generation of Reactive Oxygen Species , 2008, Pharmaceutical Research.

[84]  A. Baldwin,et al.  Inducible phosphorylation of I kappa B alpha is not sufficient for its dissociation from NF-kappa B and is inhibited by protease inhibitors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[86]  Roman A. Laskowski,et al.  LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery , 2011, J. Chem. Inf. Model..

[87]  D. Alessi,et al.  Use of Akt Inhibitor and a Drug-resistant Mutant Validates a Critical Role for Protein Kinase B/Akt in the Insulin-dependent Regulation of Glucose and System A Amino Acid Uptake* , 2008, Journal of Biological Chemistry.

[88]  T. Tanaka,et al.  Inhibitory effects of plumbagin and juglone on azoxymethane-induced intestinal carcinogenesis in rats. , 1998, Cancer letters.

[89]  P. Kuo,et al.  Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. , 2008, Cancer letters.

[90]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[91]  P. Kuo,et al.  Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells , 2006, Molecular Cancer Therapeutics.

[92]  Ximing Xu,et al.  STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway , 2012, Journal of Biosciences.

[93]  Suneet Shukla,et al.  The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2 , 2007, Molecular Cancer Therapeutics.

[94]  Mary K Joseph,et al.  Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. , 2007, Journal of medicinal chemistry.

[95]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[96]  P. Black,et al.  In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human Glioblastomas , 2004, Clinical Cancer Research.